Literature DB >> 15655426

Comorbidity as a predictor of stage of illness for patients with breast cancer.

Steven T Fleming1, Holly G Pursley, Beth Newman, Dmitri Pavlov, Kun Chen.   

Abstract

OBJECTIVE: The purpose of this research was to determine whether comorbidity affects the stage at which breast cancer is diagnosed.
METHODS: Data from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute (NCI) was merged with Medicare claims for 17,468 women diagnosed with breast cancer from 1993 to 1995.
RESULTS: Women with cardiovascular disease, musculoskeletal disorders, mild-to-moderate gastrointestinal disease, and nonmalignant benign breast disease had a 13%, 7%, 14%, and 24% lower odds, respectively, of being diagnosed with advanced breast cancer. Women with diabetes, other endocrine disorders, psychiatric disorders, or hematologic disorders increased the odds of a late-stage diagnosis by 19%, 11%, 20%, and 19% respectively. Mammography screening and contact with the medical care system decreased the odds of late-stage diagnosis. DISCUSSION: Four hypotheses are suggested to explain this link between comorbid illness and stage at diagnosis: (1) the "surveillance" hypothesis, (2) the "physiological" hypothesis, (3) the "competing demand" hypothesis, and (4) the "death from other causes" hypothesis.
CONCLUSIONS: Comorbidity may complicate the diagnostic decision-making process for breast cancer. The results suggest that contact with the medical care system improves the odds of early-stage diagnosis. Thus, barriers to access for people with chronic conditions may exacerbate those chronic conditions and increase the odds of late-stage breast cancer.

Entities:  

Mesh:

Year:  2005        PMID: 15655426     DOI: 10.1097/00005650-200502000-00006

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  59 in total

1.  Different effects of multiple health status indicators on breast and colorectal cancer screening in a nationally representative US sample.

Authors:  Anjali D Deshpande; Amy McQueen; Elliot J Coups
Journal:  Cancer Epidemiol       Date:  2011-11-11       Impact factor: 2.984

2.  Diabetes, Abnormal Glucose, Dyslipidemia, Hypertension, and Risk of Inflammatory and Other Breast Cancer.

Authors:  Catherine Schairer; Shahinaz M Gadalla; Ruth M Pfeiffer; Steven C Moore; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-01-13       Impact factor: 4.254

Review 3.  Comorbid disease and cancer: the need for more relevant conceptual models in health services research.

Authors:  Jane M Geraci; Carmen P Escalante; Jean L Freeman; James S Goodwin
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

4.  Rural Residents' Perspectives on Multiple Morbidity Management and Disease Prevention.

Authors:  Shoshana H Bardach; Nancy E Schoenberg; Yelena N Tarasenko; Steven T Fleming
Journal:  J Appl Gerontol       Date:  2011-12

Review 5.  Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review.

Authors:  Elisabetta Patorno; Elizabeth M Garry; Amanda R Patrick; Sebastian Schneeweiss; Victoria G Gillet; Olesya Zorina; Dorothee B Bartels; John D Seeger
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

Review 6.  Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer.

Authors:  A G Renehan; H-C Yeh; J A Johnson; S H Wild; E A M Gale; H Møller
Journal:  Diabetologia       Date:  2012-04-04       Impact factor: 10.122

7.  Risk of advanced-stage breast cancer among older women with comorbidities.

Authors:  Shagufta Yasmeen; Rebecca A Hubbard; Patrick S Romano; Weiwei Zhu; Berta M Geller; Tracy Onega; Bonnie C Yankaskas; Diana L Miglioretti; Karla Kerlikowske
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-28       Impact factor: 4.254

8.  Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates?

Authors:  Dejana Braithwaite; Weiwei Zhu; Rebecca A Hubbard; Ellen S O'Meara; Diana L Miglioretti; Berta Geller; Kim Dittus; Dan Moore; Karen J Wernli; Jeanne Mandelblatt; Karla Kerlikowske
Journal:  J Natl Cancer Inst       Date:  2013-02-05       Impact factor: 13.506

9.  Genetic polymorphisms of diabetes-related genes, their interaction with diabetes status, and breast cancer incidence and mortality: The Long Island Breast Cancer Study Project.

Authors:  Humberto Parada; Rebecca J Cleveland; Kari E North; June Stevens; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella; Maria E Martinez; Marilie D Gammon
Journal:  Mol Carcinog       Date:  2018-12-11       Impact factor: 4.784

10.  Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems.

Authors:  S Yousuf Zafar; Amy P Abernethy; David H Abbott; Steven C Grambow; Jennifer E Marcello; James E Herndon; Krista L Rowe; Jane T Kolimaga; Leah L Zullig; Meenal B Patwardhan; Dawn T Provenzale
Journal:  BMC Cancer       Date:  2008-11-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.